NCT02243176View on ClinicalTrials.gov

24-Week, Multicenter, Randomized, Parallel-group, Open-label, Active Controlled Phase IV Study to Assess the Efficacy, Safety and Tolerability of Saxagliptin Compared With Acarbose When in Combination With Metformin in Patients With T2D Inadequately Controlled With Metformin Monotherapy

PHASE4CompletedINTERVENTIONAL

Enrollment

689

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

Saxagliptin

The dose of saxaglitpin will be 5mg oral qd.

DRUG

Acarbose

Patients who take acarbose will begin with 50mg tid for 7 days then be titrated to 100mg tid till the end of the study. A call visit (V5) will be performed at Week 1 for adverse event and reminding patients the dose titration of acrabose.

Trial Locations (1)

Unknown

Research Site, Shanghai